Table 2.
Relationship between exosome-derived ncRNAs and clinicopathologic characteristics in BCa.
| Type of ncRNAs | Exosomal ncRNAs | Clinical sample | Dysregulation | Number of patients | Gender | Age | Tumor size | Tumor grade | T stage | LMN | DM | Number of tumors | Recurrence | Ref./PMID |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CircRNA | circPRMT5 | Serum | Up | 71 | No | No | – | – | Yes | Yes | – | – | – | 30305293 |
| LncRNA | ANRIL | Urine | Up | 30 | – | – | No | No | No | – | – | – | No | 32231490 |
| LncRNA | BCYRN1 | Urine | Up | 210 | No | No | – | No | Yes | Yes | – | – | – | 34323412 |
| LncRNA | PCAT-1 | Urine | Up | 30 | – | – | No | No | No | – | – | – | No | 32231490 |
| LncRNA | MALAT1 | Urine | Up | 80 | No | No | – | No | No | No | – | – | Yes | 30268126 |
| LncRNA | PCAT-1 | Urine | Up | 80 | No | No | – | No | Yes | No | – | – | Yes | 30268126 |
| LncRNA | SPRY4-IT1 | Urine | Up | 80 | No | No | – | No | Yes | No | – | – | – | 30268126 |
| LncRNA | H19 | Serum | Up | 52 | No | No | – | No | Yes | Yes | – | – | – | 30576305 |
| LncRNA | LNMAT2 | Urine | Up | 266 | No | No | – | No | No | Yes | Yes | – | – | 31593555 |
| LncRNA | PCAT-1 | Serum | Up | 160 | No | No | – | Yes | No | No | – | – | – | 30467945 |
| LncRNA | UBC1 | Serum | Up | 160 | No | No | – | No | Yes | Yes | – | – | – | 30467945 |
| LncRNA | SNHG16 | Serum | Up | 160 | No | No | – | No | Yes | No | – | – | – | 30467945 |
BCa, bladder cancer; ncRNAs, noncoding RNAs; circRNA, circular RNA; LncRNA, long noncoding RNA; LNM, lymph nodes metastasis; NAT, adjacent noncancerous tissues; LNM, lymph node metastasis; DM, distant metastasis.